Malaysian Clinical Laboratories Market, Forecast to 2025

Malaysian Clinical Laboratories Market, Forecast to 2025

Shift toward Preventive Healthcare is Driving Market Growth

RELEASE DATE
28-Mar-2019
REGION
Asia Pacific
Research Code: 9AB9-00-A4-00-00
SKU: HC03148-AP-MR_22949

$1,500.00

Special Price $1,125.00 save 25 %

In stock
SKU
HC03148-AP-MR_22949

$1,500.00

$1,125.00 save 25 %

DownloadLink

Pay by invoice

ENQUIRE NOW

Description

The market for healthcare services in Malaysia is less developed, with many clinical testing services being unavailable outside of cities. Unsubstantiated disease and unconfirmed mortality diagnoses are common in the country despite universal care, significant mixed investment in the local healthcare system, and health expenditure favourable to other middle-income nations. With demographic shifts such as population aging, increasing life expectancy, and growth of non-communicable diseases, the demand for healthcare is expected to grow. Hence, there is increasing pressure on stakeholders to restructure the healthcare system, with an emphasis on allowing private facilities to play a more significant role.

The Malaysian clinical laboratories testing (CLT) market is expected to continue growing, driven by a shift toward preventive healthcare, rising demand, population aging, and growth of medical tourism. Overall, the market is attractive for international players to invest in and capitalize on the available opportunities.Malaysia as a developing country is slowly consolidating its position at the forefront of global healthcare with affordable services and increase in medical tourism. In 2016, the Government of Malaysia prioritized healthcare spending by injecting $5.2 billion into the market. Malaysia’s healthcare system consists of two tiers: a state-owned universal healthcare system for national citizens and a private sector that serves the more affluent citizens of the country and international patients. Majority of the tests are conducted in-house, with specialized testing such as molecular diagnostics being referred out due to inadequate laboratory facilities. This is observed mainly in district and secondary public hospitals and in private hospitals situated in rural areas. Private independent laboratories have started spreading out to capture more direct consumers through health screening packages, while maintaining their relationships with hospitals and private clinics to receive send-out samples.

The Government of Malaysia seeks to facilitate market growth by encouraging private investments in areas such as manufacturing of pharmaceutical products and medical devices, clinical research, and aged care services and by supporting collaborative efforts between public and private healthcare providers. Collectively, the 40 healthcare projects announced under the National Key Economic Areas (NKEA) program are projected to create 26,966 jobs and generate an income of $1.70 billion, recording $1.28 billion in new investments by 2020.

Key Issues Addressed

  • How has Malaysia’s clinical laboratories market changed over the years?
  • What impact will the new regulations have on laboratories? What are the new procedures that need to be adopted to gain approvals? How will this affect manufacturers?
  • Which type of testing is experiencing maximum growth and why?
  • What are the new business models that can transform care delivery?
  • Which are the segments that offer substantial opportunities for manufacturers?
  • What are the acquisition trends witnessed in the last few years? How will this change?

Table of Contents

Key Findings

Key Trends

Key Questions this Study will Answer

Executive Summary—Market Engineering Measurements

Key Companies to Watch

3 Big Predictions

Scope and Segmentation

Market Segmentation

Market Segmentation (continued)

Market Overview

Market Overview (continued)

Market Overview (continued)

Market Overview (continued)

Market Overview (continued)

Market Overview (continued)

Market Overview (continued)

Impact of Trends on Clinical Laboratories Market

Defining Healthcare Trends in the Future

Market Drivers

Drivers Explained

Market Restraints

Restraints Explained

Impact Mapping of Drivers and Restraints

Malaysia Private Laboratory—An Overview

Private Laboratory Regulatory

Healthcare Foreign Direct Investment Regulations

Forecast Assumptions

Market Engineering Measurements

Revenue Forecast

Revenue Forecast by Segment

Revenue Forecast Discussion

Competitive Structure

Clinical Laboratories Market Access in Malaysia—Game-changing Strategies

Merger, Acquisition, and Partnership Assessment

Market Share Analysis

Company Information—Pathlab

Company Information—Gribbles

Company Information—BP Healthcare

Industry Value Chain

Major Growth Opportunities

Growth Opportunity 1—Test Type

Growth Opportunity 2—Clinical Lab Automation

Growth Opportunity 3—Data Management

Growth Opportunity 4—Super-specialty Clinic

Strategic Imperatives for Malaysia’s Clinical Laboratories Market

3 Big Predictions

Legal Disclaimer

List of Exhibits

List of Exhibits (continued)

The Frost & Sullivan Story

Value Proposition—Future of Your Company & Career

Global Perspective

Industry Convergence

360º Research Perspective

Implementation Excellence

Our Blue Ocean Strategy

Related Research
The market for healthcare services in Malaysia is less developed, with many clinical testing services being unavailable outside of cities. Unsubstantiated disease and unconfirmed mortality diagnoses are common in the country despite universal care, significant mixed investment in the local healthcare system, and health expenditure favourable to other middle-income nations. With demographic shifts such as population aging, increasing life expectancy, and growth of non-communicable diseases, the demand for healthcare is expected to grow. Hence, there is increasing pressure on stakeholders to restructure the healthcare system, with an emphasis on allowing private facilities to play a more significant role. The Malaysian clinical laboratories testing (CLT) market is expected to continue growing, driven by a shift toward preventive healthcare, rising demand, population aging, and growth of medical tourism. Overall, the market is attractive for international players to invest in and capitalize on the available opportunities.Malaysia as a developing country is slowly consolidating its position at the forefront of global healthcare with affordable services and increase in medical tourism. In 2016, the Government of Malaysia prioritized healthcare spending by injecting $5.2 billion into the market. Malaysia’s healthcare system consists of two tiers: a state-owned universal healthcare system for national citizens and a private sector that serves the more affluent citizens of the country and international patients. Majority of the tests are conducted in-house, with specialized testing such as molecular diagnostics being referred out due to inadequate laboratory facilities. This is observed mainly in district and secondary public hospitals and in private hospitals situated in rural areas. Private independent laboratories have started spreading out to capture more direct consumers through health screening packages, while maintaining their relationships with hospitals and privat
More Information
No Index No
Podcast No
Author Sanjeev Kumar
Industries Healthcare
WIP Number 9AB9-00-A4-00-00
Is Prebook No
GPS Codes 9600-B1,99C1-B1,99C6-B1,9837-B1,9611-B1,9627-B1